The same study, unlike our study, did not only include patients with PSA<10 ng/ml but included patients with all PSA levels and reported that the patients had a median PSA level of 9 (range, 0.7-48) ng/ml, both of which might be the reasons for the higher cancer detection rates determined in that study as compared to those of our study. The gene discussed is KLK3; the disease is cancer.